Earli

About:

Earli develops genetic constructs for early cancer detection and targeted therapy.

Website: https://www.earli.com/

Twitter/X: goearli

Top Investors: Khosla Ventures, Alumni Ventures, Andreessen Horowitz, Sands Capital Ventures, Perceptive Advisors

Description:

Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics.

Total Funding Amount:

$59.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2018-06-13

Contact Email:

join(AT)earli.com

Founders:

Cyriac Roeding, David Suhy, Sanjiv Gambhir

Number of Employees:

11-50

Last Funding Date:

2024-08-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai